Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

The inhibition of histone deacetylase (HDAC) can induce differentiation, growth arrest, and apoptosis in cancer cells. This phase II multicenter study was undertaken to estimate the efficacy of belinostat, a potent inhibitor of both class I and class II HDAC enzymes, for the treatment of myelodyspla...

Full description

Saved in:
Bibliographic Details
Main Authors: Cashen, Amanda, Juckett, Mark, Jumonville, Alcee, Litzow, Mark, Flynn, P. J., Eckardt, John, LaPlant, Betsy, Laumann, Kristina, Erlichman, Charles, DiPersio, John
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557843/
https://ncbi.nlm.nih.gov/pubmed/21538061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-011-1240-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items